(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 December 2017 (21.12.2017)

WIPO | PCT

(10) International Publication Number
WO 2017/218843 A1

(51) International Patent Classification:

C07D 403/12 (2006.01)	*A61K 31/506* (2006.01)
C07D 401/14 (2006.01)	*A61K 31/5365* (2006.01)
C07D 405/14 (2006.01)	*A61K 31/519* (2006.01)
C07D 413/14 (2006.01)	*A61K 31/5377* (2006.01)
C07D 403/14 (2006.01)	*A61P 25/00* (2006.01)
C07D 409/14 (2006.01)	*A61P 25/16* (2006.01)
C07D 417/14 (2006.01)	*A61P 25/28* (2006.01)
C07D 487/04 (2006.01)	*A61P 25/14* (2006.01)
C07D 491/20 (2006.01)	*A61P 35/00* (2006.01)
C07D 498/04 (2006.01)	*A61P 29/00* (2006.01)

(21) International Application Number:
PCT/US2017/037782

(22) International Filing Date:
15 June 2017 (15.06.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/350,876	16 June 2016 (16.06.2016)	US
62/417,151	03 November 2016 (03.11.2016)	US
62/476,581	24 March 2017 (24.03.2017)	US
62/510,711	24 May 2017 (24.05.2017)	US

(71) Applicant: **DENALI THERAPEUTICS INC.** [US/US]; 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US).

(72) Inventors: **ESTRADA, Anthony A.**; c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US). **FENG, Jianwen A.**; c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US). **LYSSIKATOS, Joseph P.**; c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US). **SWEENEY, Zachary K.**; c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US). **DE VICENTE FIDALGO, Javier**; c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US).

(74) Agent: **TANNER, Lorna L.** et al.; Sheppard Mullin Richter & Hampton LLP, 379 Lytton Avenue, Palo Alto, California 94301-1479 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

WO 2017/218843 A1

(54) Title: PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS



(I)

(57) Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof. (Formula (I))